Analytical Data
-
Gene name
Collagen alpha-1(II) chain/COL2A1
- Application
-
Alternative Names
COL2-A1; COL2A1; SEDC; Chondrocalcin; Collagen Alpha-1(II)Chain; Primary Osteoarthritis,Spondyloepiphyseal Dysplasia,Congenital
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 95% as determined by SDS-PAGE.
-
Uniprot
P02458
-
Expression Region
Ser1386~Pro1467
-
Molecular Weight
13kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Collagen alpha-1(II) chain, encoded by the COL2A1 gene, is a key component of type II collagen, primarily found in cartilage, which provides structural support and resilience to cartilage tissues. Its importance in maintaining cartilage integrity makes it vital for normal joint function and overall skeletal development. Mutations in the COL2A1 gene are linked to various connective tissue disorders, including Achondrogenesis and Osteogenesis Imperfecta, which can lead to severe skeletal abnormalities. The recombinant protein of COL2A1 is increasingly being studied for its potential applications in regenerative medicine, particularly for cartilage repair and tissue engineering. The ability to produce recombinant COL2A1 allows for a detailed understanding of its molecular properties and interactions within the extracellular matrix. Furthermore, this research assists in developing biomimetic materials that can mimic the properties of native cartilage, promoting the repair and regeneration of damaged tissues. As the demand for effective treatments for cartilage-related diseases and injuries rises, the study of COL2A1 recombinant protein holds promise for advancing therapeutic strategies and improving patient outcomes in orthopedics and rheumatology.
